Szpital Dzieciecy Polanki Im. Macieja Plazynskiego W Gdansku Sp. z o.o.
- Address
- Ul. Polanki 119, 80-308 Gdansk, Poland
Szpital Dziecięcy Polanki - Pediatric Cystic Fibrosis Research Center
Szpital Dziecięcy Polanki im. Macieja Płażyńskiego w Gdańsku is a specialized pediatric hospital actively engaged in advanced clinical research for children with rare genetic diseases. The center demonstrates particular expertise in conducting Phase 3 clinical trials evaluating innovative CFTR modulator therapies for patients with cystic fibrosis.
- Long-term safety and tolerability studies of novel triple combination CFTR modulator therapies
- Advanced treatment protocols for cystic fibrosis using next-generation corrector and potentiator combinations
- Comprehensive pulmonary disease management in pediatric populations
The hospital's participation in multinational cystic fibrosis research initiatives reflects its commitment to advancing precision medicine approaches for rare genetic disorders. Through rigorous clinical investigation of emerging VX-121 combination therapy, the center contributes to the development of breakthrough treatments that may significantly improve outcomes for children living with cystic fibrosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vertex Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Dzieciecy Polanki Im. Macieja Plazynskiego W Gdansku Sp. z o.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Long-term Safety and Efficacy of Tezacaftor, Deutivacaftor, and Vanzacaftor Combination Therapy in Patients with Cystic Fibrosis | Vertex Pharmaceuticals Inc. | Phase III | Not Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tezacaftor | 2 | Unknown | 2022-11-08 | 2023-02-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.